IDEAYA Biosciences
IDYA | NASDAQ
$30.36
-$1.47 (-4.62%)
At close: Nov 16, 2026, 4:00 PM ET
$30.36
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
IDEAYA Biosciences Company Profile
Company profile explainedCompany Profile
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Yujiro S. Hata | Founder, President, CEO & Chairman |
| Douglas Snyder | Chief Legal Officer |
| Joshua Bleharski | Chief Financial Officer |
| Paul A. Barsanti | Chief Technology Officer |
| Andres Ruiz Briseno | Chief Accounting Officer |
| Daniel A. Simon | Chief Business Officer |
| Darrin Beaupre | Chief Medical Officer |
| Francine Zelaya | Senior VP & Head of Human Resources |
| Jasgit Sachdev | Senior Vice President of Late Phase Clinical Development & Strategy |
| Michael A. White | President of Research & Development |
| Mick O'Quigley | Senior Vice President of Medical Writing & Project Management |
| Stuart Dorman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 08, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 09, 2026 | 4 | Filing |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
IDEAYA Biosciences
| Country | United States |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Yujiro S. Hata |
Contact Details
7000 Shoreline Court South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | IDYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001676725 |
| CUSIP Number | 45166A102 |
| ISIN Number | US45166A1025 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / seekingalpha.comIDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript
- 1 day ago / gurufocus.comIDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
- 13 days ago / prnewswire.comIDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
- 14 days ago / zacks.comIDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
- 14 days ago / prnewswire.comIDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
- 21 days ago / zacks.comIDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- 2 months ago / prnewswire.comIDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
- 2 months ago / seekingalpha.comIDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 3 months ago / prnewswire.comIDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
- 3 months ago / gurufocus.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Add to Watchlist
Select watchlists to add or remove IDYA